Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatitis acute,Human,-1.380211241711606,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022325/S-000, page:56 PDF 4383k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/905fc0105fb7a9f0722d63ca5ee33b94?reference=56,2008.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatitis acute,Human,-0.6989700043360189,Repeated,Intravenous,"EMA approval document: Assessment Report EMA/916359/2019; EMEA/H/C/000788/P46/046, page:30 PDF 1307k",https://www.pharmapendium.com/browse/ema/Anidulafungin/8db8b31deadd98115829b6333f16e5f2?reference=30,2018.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Aztreonam,C[C@H]1[C@H](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O,Hepatitis acute,Human,-0.47712125471966244,Repeated,Inhalation,"FDA approval package document: Medical/Clinical Review 050814/S-000, page:147 PDF 2453k",https://www.pharmapendium.com/browse/fda/Aztreonam/bb144edde8247201da42a76afeb3318d?reference=147,2009.0,C[CH]1[CH](NC(=O)C(=N/OC(C)(C)C(O)=O)\C2=CSC(N)=N2)C(=O)N1S(O)(=O)=O
Brexpiprazole,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1,Hepatitis acute,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 205422/S-000 Part 04, page:81 PDF 20059k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/00ccb22ace460844be09f496a697ac0d?reference=81,2014.0,O=C1NC2=CC(OCCCCN3CCN(CC3)C3=C4C=CSC4=CC=C3)=CC=C2C=C1
Carteolol Hydrochloride,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2,Hepatitis acute,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 019204 Part 01, page:2 PDF 5749k",https://www.pharmapendium.com/browse/fda/Carteolol Hydrochloride/7500040fe3a502b3c82f20206fa1b9cb?reference=2,1988.0,CC(C)(C)NCC(O)COC1=CC=CC2=C1CCC(=O)N2
Cefdinir,[H][C@]12SCC(C=C)=C(N1C(=O)[C@H]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O,Hepatitis acute,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Printed Labeling 050749/S-000, page:23 PDF 1493k",https://www.pharmapendium.com/browse/fda/Cefdinir/10c4f05e362d284ea2ef7800cb8bc9b3?reference=23,1997.0,[H][C]12SCC(C=C)=C(N1C(=O)[CH]2NC(=O)C(=N/O)\C1=CSC(N)=N1)C(O)=O
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hepatitis acute,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/386332/2017; EMEA/H/C/003819/II/0012, page:71 PDF 6439k",https://www.pharmapendium.com/browse/ema/Ceritinib/0ce99201261a9d8e84a0cbcfc52ed714?reference=71,2017.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Cetirizine Hydrochloride,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1,Hepatitis acute,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022155/S-000 Part 01, page:62 PDF 7190k",https://www.pharmapendium.com/browse/fda/Cetirizine Hydrochloride/5477eee343e2d9bd7ae6807c4260c83f?reference=62,2007.0,OC(=O)COCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1
Cladribine,NC1=NC(Cl)=NC2=C1N=CN2[C@@H]1C[C@H](O)[C@@H](CO)O1,Hepatitis acute,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022561/S-000 Part 04, page:23 PDF 4930k",https://www.pharmapendium.com/browse/fda/Cladribine/1c5c8bb5770707770a89e05f34cb8828?reference=23,2010.0,NC1=NC(Cl)=NC2=C1N=CN2[CH]1C[CH](O)[CH](CO)O1
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatitis acute,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019201/S-001, S-002, S-003, S-005, S-007, S-009, S-010, S-013, S-014, S-015, S-019, S-021 Part 06, page:18 PDF 5413k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/c56ad2267611ad95c9ab82329518aad8?reference=18,1988.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatitis acute,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:29 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=29,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Efavirenz,FC(F)(F)[C@]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1,Hepatitis acute,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:24 PDF 861k",https://www.pharmapendium.com/browse/ema/Efavirenz/096c26d9f63461f688969abc7108c6b3?reference=24,2019.0,FC(F)(F)[C]1(OC(=O)NC2=CC=C(Cl)C=C12)C#CC1CC1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatitis acute,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:24 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=24,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatitis acute,Human,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Environmental Review 020499/S-000 Part 03, page:11 PDF 1169k",https://www.pharmapendium.com/browse/fda/Ketoprofen/1290668264afac43a077029ae7c5def7?reference=11,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Liraglutide,CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CN=CN1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O,Hepatitis acute,Human,-0.9030899869919435,Repeated,Subcutaneous,"FDA approval package document: Approval Package 022341/S-027 Part 23, page:46 PDF 9721k",https://www.pharmapendium.com/browse/fda/Liraglutide/b5167110732dfcd7a8cc0c3da576ecf4?reference=46,2016.0,CCCCCCCCCCCCCCCC(=O)N[CH](CCC(=O)NCCCC[CH](NC(=O)[CH](C)NC(=O)[CH](C)NC(=O)[CH](CCC(N)=O)NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](CC(C)C)NC(=O)[CH](CC1=CC=C(O)C=C1)NC(=O)[CH](CO)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC(O)=O)NC(=O)[CH](CO)NC(=O)[CH](NC(=O)[CH](CC1=CC=CC=C1)NC(=O)[CH](NC(=O)CNC(=O)[CH](CCC(O)=O)NC(=O)[CH](C)NC(=O)[CH](N)CC1=CN=CN1)[CH](C)O)[CH](C)O)C(C)C)C(=O)N[CH](CCC(O)=O)C(=O)N[CH](CC1=CC=CC=C1)C(=O)N[CH]([CH](C)CC)C(=O)N[CH](C)C(=O)N[CH](CC1=CNC2=C1C=CC=C2)C(=O)N[CH](CC(C)C)C(=O)N[CH](C(C)C)C(=O)N[CH](CCCNC(N)=N)C(=O)NCC(=O)N[CH](CCCNC(N)=N)C(=O)NCC(O)=O)C(O)=O
Mexiletine Hydrochloride,CC(N)COC1=C(C)C=CC=C1C,Hepatitis acute,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/831802/2018; EMEA/H/C/004584/0000, page:116 PDF 3055k",https://www.pharmapendium.com/browse/ema/Mexiletine Hydrochloride/0339e2432f1279187517a7d5ce5d49a6?reference=116,2018.0,CC(N)COC1=C(C)C=CC=C1C
Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Hepatitis acute,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Label 201152/S-000, page:6 PDF 507k",https://www.pharmapendium.com/browse/fda/Nevirapine/18b79028e6ff80260708a5a806a0b4ce?reference=6,2011.0,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1
Olopatadine Hydrochloride,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12,Hepatitis acute,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021861/S-000 Part 01, page:68 PDF 1704k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/9eb9dbed0818da3a35597e43417acc9f?reference=68,2006.0,CN(C)CC\C=C1\C2=CC=CC=C2COC2=CC=C(CC(O)=O)C=C12
Raltegravir Potassium,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1,Hepatitis acute,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022145/S-000 Part 01, page:80 PDF 6696k",https://www.pharmapendium.com/browse/fda/Raltegravir Potassium/af40780e21e1a3c69e5027a0fcf4730c?reference=80,2007.0,CN1C(=O)C([O-])=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatitis acute,Human,-0.3010299956639812,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022406/S-000 Part 16, page:6 PDF 394k",https://www.pharmapendium.com/browse/fda/Rivaroxaban/ba755011cb37ec9d494dd6be76a6ea40?reference=6,2009.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Selpercatinib,COC1=CC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=N1,Hepatitis acute,Human,-2.380211241711606,Repeated,Oral,"FDA approval package document: Approval Package 213246/S-000 Part 08, page:76 PDF 1950k",https://www.pharmapendium.com/browse/fda/Selpercatinib/0bc2eb29c35e2815b928188021ea505d?reference=76,2020.0,COC1=CC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=N1
Teriflunomide,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F,Hepatitis acute,Human,-1.146128035678238,Repeated,Oral,"EMA approval document: ANNEX I, page:10 PDF 581k",https://www.pharmapendium.com/browse/ema/Teriflunomide/c8d2e93a6d675dc92650f7e25b1ec03a?reference=10,2021.0,C\C(O)=C(/C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Hepatitis acute,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Assessment Report EMA/70192/2018; EMEA/H/A-31/1496, page:4 PDF 374k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/c129333ea657fa9e9bb2fdc3911b5801?reference=4,2020.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Vigabatrin,NC(CCC(O)=O)C=C,Hepatitis acute,Human,-3.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020427/S-000 Part 02, page:46 PDF 6981k",https://www.pharmapendium.com/browse/fda/Vigabatrin/8df119ca2ebfd8c7300d5bc513a92a8d?reference=46,2009.0,NC(CCC(O)=O)C=C
Voxelotor,CC(C)N1N=CC=C1C1=NC=CC=C1COC1=C(C=O)C(O)=CC=C1,Hepatitis acute,Human,-2.9542425094393248,Repeated,Oral,"FDA approval package document: Approval Package 213137/S-000 Part 07, page:10 PDF 2058k",https://www.pharmapendium.com/browse/fda/Voxelotor/809742f5ff5d7ddd3d32484c317d6a07?reference=10,2019.0,CC(C)N1N=CC=C1C1=NC=CC=C1COC1=C(C=O)C(O)=CC=C1
